Genetic Technologies Ltd. ADR (GENE): Price and Financial Metrics
GET POWR RATINGS... FREE!
GENE POWR Grades
- GENE scores best on the Sentiment dimension, with a Sentiment rank ahead of 55.68% of US stocks.
- GENE's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
- GENE ranks lowest in Quality; there it ranks in the 0th percentile.
GENE Stock Summary
- For GENE, its debt to operating expenses ratio is greater than that reported by merely 7.08% of US equities we're observing.
- GENE's price/sales ratio is 616.85; that's higher than the P/S ratio of 98.96% of US stocks.
- As for revenue growth, note that GENE's revenue has grown 1,122.17% over the past 12 months; that beats the revenue growth of 99.08% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Genetic Technologies Ltd are ADXS, LQDA, AQB, BIOC, and SLS.
- GENE's SEC filings can be seen here. And to visit Genetic Technologies Ltd's official web site, go to www.gtglabs.com.
GENE Stock Price Chart Interactive Chart >
GENE Price/Volume Stats
| Current price | $2.90 | 52-week high | $8.18 |
| Prev. close | $3.01 | 52-week low | $2.74 |
| Day low | $2.87 | Volume | 123,600 |
| Day high | $3.02 | Avg. volume | 965,841 |
| 50-day MA | $3.18 | Dividend yield | N/A |
| 200-day MA | $3.90 | Market Cap | 44.59M |
Genetic Technologies Ltd. ADR (GENE) Company Bio
Genetic Technologies Ltd. is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. It operates through the USA and Australia geographical segments. The firm's product BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.
Latest GENE News From Around the Web
Below are the latest news stories about Genetic Technologies Ltd that investors may wish to consider to help them evaluate GENE as an investment opportunity.
Genetic Technologies Reports Q1 FY22 ResultsGenetype MultiTest submitted for regulatory approval as commercialization plans gather momentum increase in cash receipts over prior quarterMELBOURNE, Australia, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in Genomics based tests in health, wellness and serious disease provides its results for its first quarter of fiscal year 2022, ended September 30, 2021. Highlights Cash receipts of A$850k, a material increase on th |
GENE Delivers Material 12-Fold Increase in Revenue in the Quarter Ended September 2021Commercialisation plans gather momentumMELBOURNE, Australia, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease, announces a 12-fold increase in revenue generated during the September 2021 quarter to A$850k1. Highlights: Delivering a material 12-fold increase in customer receipts to A$850k, versus June 2021 quarterRevenue primarily derived from license and resa |
Genetic Technologies Limited Interview to Air on Bloomberg TV (U.S.) on the RedChip Money Report®MELBOURNE, Australia, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in Genomics based tests in health, wellness and serious disease, today announced that an interview with CEO Simon Morriss, discussing the advancements on their commercialization plans, the recent acquisition of EasyDNA and the associated near term material revenue increase, will air on The RedChip Money Report® on Bloomberg TV (U.S.), Saturday, October |
GENE Embarks on Breakthrough African American Collaboration for Breast Cancer as Part of Its Commitment to Ethnic DiversityStudy to focus on women of African American descent for expanded polygenic risk testMELBOURNE, Australia, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business today announced that they have entered into a strategic collaboration with the Institute of Public Health in St Louis USA for the purpose of expanding the predictive capabilities of the GeneType for Breast Cancer product |
BelHealth Completes Asset Sale of General Genetics Corp.September 9, 2021–BelHealth Investment Partners, LLC ("BelHealth") is pleased to announce that it has completed the sale of assets of the international division of General Genetics Corporation (GGC), a provider of relationship and clinical genetic testing services, to Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company ("GTG"). The transaction was structured in a combination of cash and stock of GTG. |
GENE Price Returns
| 1-mo | -8.23% |
| 3-mo | -14.71% |
| 6-mo | -32.24% |
| 1-year | -9.09% |
| 3-year | -38.56% |
| 5-year | -46.69% |
| YTD | -19.44% |
| 2020 | 80.90% |
| 2019 | -9.54% |
| 2018 | -52.59% |
| 2017 | 7.41% |
| 2016 | -59.70% |
Continue Researching GENE
Want to see what other sources are saying about Genetic Technologies Ltd's financials and stock price? Try the links below:Genetic Technologies Ltd (GENE) Stock Price | Nasdaq
Genetic Technologies Ltd (GENE) Stock Quote, History and News - Yahoo Finance
Genetic Technologies Ltd (GENE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...